Search

Your search keyword '"Kuil, Annemieke"' showing total 8 results
Start Over Author "Kuil, Annemieke" Publisher american society of hematology
8 results on '"Kuil, Annemieke"'

2. Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

Author

Chang, Betty Y., primary, Francesco, Michelle, additional, De Rooij, Martin F. M., additional, Magadala, Padmaja, additional, Steggerda, Susanne M., additional, Huang, Min Mei, additional, Kuil, Annemieke, additional, Herman, Sarah E. M., additional, Chang, Stella, additional, Pals, Steven T., additional, Wilson, Wyndham, additional, Wiestner, Adrian, additional, Spaargaren, Marcel, additional, Buggy, Joseph J., additional, and Elias, Laurence, additional

Published
2013
Full Text
View/download PDF

8. Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.

Author

Chang, Betty Y., Francesco, Michelle, De Rooij, Martin F. M., Magadala, Padmaja, Steggerda, Susanne M., Min Mei Huang, Kuil, Annemieke, Herman, Sarah E. M., Chang, Stella, Pals, Steven T., Wilson, Wyndham, Wiestner, Adrian, Spaargaren, Marcel, Buggy, Joseph J., and Elias, Laurence

Subjects
*PROTEIN-tyrosine kinases, *LYMPHOCYTIC leukemia, *LYMPHOPROLIFERATIVE disorders, *GENOTYPE-environment interaction, *CYTOKINES
Abstract

Ibrutinib (PCI-32765) is a highly potent oral Bruton tyrosine kinase (BTK) inhibitor in clinical development for treating B-cell lymphoproliferative diseases. Patients with chronic lymphocytic leukemia (CLL) often show marked, transient increases of circulating CLL cells following ibrutinib treatments, as seen with other inhibitors of the B-cell receptor (BCR) pathway. In a phase 1 study of ibrutinib, we noted similar effects in patients with mantle cell lymphoma (MCL). Here, we characterize the patterns and phenotypes of cells mobilized among patients with MCL and further investigate the mechanism of this effect. Peripheral blood CD19+ CD5+ cells from MCL patients were found to have significant reduction in the expression of CXCR4, CD38, and Ki67 after 7 days of treatment. In addition, plasma chemokines such as CCL22, CCL4, and CXCL13 were reduced 40% to 60% after treatment. Mechanistically, ibrutinib inhibited BCR- and chemokine-mediated adhesion and chemo-taxis of MCL cell lines and dose-dependently inhibited BCR, stromal cell, and CXCL12/ CXCL13 stimulations of pBTK, PPLCγ2, pERK, or pAKT. Importantly, ibrutinib inhibited migration of MCL cells beneath stromal cells in coculture. We propose that BTK is essential for the homing of MCL cells into lymphoid tissues, and its inhibition results in an egress of malignant cells into peripheral blood. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results